Literature DB >> 16442496

Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC.

Hisashi Murakami1, Ryuichiro Murakami, Fukushi Kambe, Xia Cao, Ryotaro Takahashi, Toru Asai, Toshihisa Hirai, Yasushi Numaguchi, Kenji Okumura, Hisao Seo, Toyoaki Murohara.   

Abstract

Fenofibrate improves endothelial function by lipid-lowering and anti-inflammatory effects. Additionally, fenofibrate has been demonstrated to upregulate endothelial nitric oxide synthase (eNOS). AMP-activated protein kinase (AMPK) has been reported to phosphorylate eNOS at Ser-1177 and stimulate vascular endothelium-derived nitric oxide (NO) production. We report here that fenofibrate activates AMPK and increases eNOS phosphorylation and NO production in human umbilical vein endothelial cells (HUVEC). Incubation of HUVEC with fenofibrate increased the phosphorylation of AMPK and acetyl-CoA carboxylase. Fenofibrate simultaneously increased eNOS phosphorylation and NO production. Inhibitors of protein kinase A and phosphatidylinositol 3-kinase failed to suppress the fenofibrate-induced eNOS phosphorylation. Neither bezafibrate nor WY-14643 activated AMPK in HUVEC. Furthermore, fenofibrate activated AMPK without requiring any transcriptional activities. These results indicate that fenofibrate stimulates eNOS phosphorylation and NO production through AMPK activation, which is suggested to be a novel characteristic of this agonist and unrelated to its effects on peroxisome proliferator-activated receptor alpha.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16442496     DOI: 10.1016/j.bbrc.2006.01.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation.

Authors:  Xing Zhong; Ling-ling Xiu; Guo-hong Wei; Yuan-yuan Liu; Lei Su; Xiao-pei Cao; Yan-bing Li; Hai-peng Xiao
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

2.  The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.

Authors:  Navin Viswakarma; Yuzhi Jia; Liang Bai; Qian Gao; Bingliang Lin; Xiaohong Zhang; Parimal Misra; Ajay Rana; Sanjay Jain; Frank J Gonzalez; Yi-Jun Zhu; Bayar Thimmapaya; Janardan K Reddy
Journal:  J Biol Chem       Date:  2013-08-13       Impact factor: 5.157

Review 3.  Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure.

Authors:  Satyam Sarma; Hossein Ardehali; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

4.  Sustained activation of AMPK ameliorates age-associated vascular endothelial dysfunction via a nitric oxide-independent mechanism.

Authors:  Lisa A Lesniewski; Melanie C Zigler; Jessica R Durrant; Anthony J Donato; Douglas R Seals
Journal:  Mech Ageing Dev       Date:  2012-03-28       Impact factor: 5.432

5.  Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.

Authors:  Dipanjan Chanda; Chul Ho Lee; Yong-Hoon Kim; Jung-Ran Noh; Don-Kyu Kim; Ji-Hoon Park; Jung Hwan Hwang; Mi-Ran Lee; Kyeong-Hoon Jeong; In-Kyu Lee; Gi Ryang Kweon; Minho Shong; Goo-Taeg Oh; John Y L Chiang; Hueng-Sik Choi
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

6.  ICAM-1-mediated endothelial nitric oxide synthase activation via calcium and AMP-activated protein kinase is required for transendothelial lymphocyte migration.

Authors:  Roberta Martinelli; Matthew Gegg; Rebecca Longbottom; Peter Adamson; Patric Turowski; John Greenwood
Journal:  Mol Biol Cell       Date:  2008-12-10       Impact factor: 4.138

7.  Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase.

Authors:  Suthat Liangpunsakul; Sung-Eun Wou; Kevin D Wineinger; Yan Zeng; Izabela Cyganek; Hiremagalur N Jayaram; David W Crabb
Journal:  Arch Biochem Biophys       Date:  2009-02-21       Impact factor: 4.013

Review 8.  Advances in the medical treatment of diabetic retinopathy.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

9.  The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.

Authors:  Wolfgang Linz; Paulus Wohlfart; Manuel Baader; Kristin Breitschopf; Eugen Falk; Hans-Ludwig Schäfer; Martin Gerl; Werner Kramer; Hartmut Rütten
Journal:  Acta Pharmacol Sin       Date:  2009-06-08       Impact factor: 6.150

10.  Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats.

Authors:  C M Sena; E Nunes; T Louro; T Proença; R Fernandes; M R Boarder; R M Seiça
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.